US81750R1023 - Common Stock
SERES THERAPEUTICS INC
NASDAQ:MCRB (5/16/2024, 7:03:22 PM)
Premarket: 0.9244 0 (0%)0.9244
-0.03 (-3.5%)
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 431 full-time employees. The company went IPO on 2015-06-26. The firm is developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead product candidate, SER-109, is designed to reduce further recurrence of CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by restructuring the gastrointestinal microbiome and modulating the metabolic landscape to address CDI. Building upon SER-109, it is developing microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and GvHD in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
SERES THERAPEUTICS INC
200 Sidney St
Cambridge MASSACHUSETTS 02139
P: 16179459626
CEO: Eric D. Shaff
Employees: 431
Website: https://www.serestherapeutics.com/
Top movers analysis one hour before the close of the markets on 2024-05-09: top gainers and losers in today's session.
Which stocks are experiencing notable movement on Thursday?
Third research collaboration signed under strategic partnership between Novo Nordisk and Flagship Pioneering to develop novel treatment approaches for...
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Here you can normally see the latest stock twits on MCRB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: